Journal of Cancer Research and Clinical Oncology · 2019 · 15 citations · 22 references
MedicineOncologySurgerySurgical OncologySurvival AnalysisThoracic OncologyLung CancerPrognostic AssessmentSurvival ModelingSurvival OutcomesSurvival PredictionTumor StagingConcordance IndexCox RegressionLow-risk Patient PopulationsLung Cancer StagingPredictive PerformancePrognostic Factors AnalysisPrognostic PredictionPrognostic Risk Assessment
PURPOSE: We combined conventional clinical and pathological characteristics and pathological architectural grading scores to develop a prognostic model to identify a specific group of patients with stage I lung adenocarcinomas with poor survival following surgery. METHODS: This retrospective study included 198 patients with stage I lung adenocarcinomas recruited from 2004 to 2013. Multivariate analyses were used to confirm independent risk factors, which were checked for internal validity using the bootstrapping method. The prognostic scores, derived from β-coefficients using the Cox regression model, classified patients into high- and low-risk groups. The predictive performance and discriminative ability of the model were assessed by the area under the receiver operating characteristic curve (AUC), concordance index (C-index) and Kaplan-Meier survival analyses. RESULTS: Three risk factors were identified: T2 (rounding of β-coefficients = 81), necrosis (rounding of β-coefficients = 67), and pathological architectural score of 5-6 (rounding of β-coefficients = 58). The final prognostic score was the sum of points. The derived prognostic scores stratified patients into low- (score ≤ 103) and high- (score > 103) risk groups, with significant differences in 5-year overall survival (high vs. low risk: 49.3% vs. 88.0%, respectively; hazard ratio: 4.55; p < 0.001). The AUC for the proposed model was 0.717. The C-index of the model was 0.693. CONCLUSION: An integrated prognostic model was developed to discriminate resected stage I adenocarcinoma patients into low- and high-risk groups, which will help clinicians select individual treatment strategies.
22
Akihiko Yoshizawa, Noriko Motoi, Gregory J. Riely et al. · Modern Pathology · 2011 · 994 citations · Full text
A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer
Hsuan‐Yu Chen, Sung‐Liang Yu, Chun‐Houh Chen et al. · New England Journal of Medicine · 2007 · 952 citations · Full text